{"id":"bevacizumab-deferred-aflibercept-group","safety":{"commonSideEffects":[{"rate":"20-40","effect":"Hypertension"},{"rate":"15-30","effect":"Proteinuria"},{"rate":"5-15","effect":"Bleeding"},{"rate":"5-10","effect":"Thromboembolic events"},{"rate":"1-2","effect":"Gastrointestinal perforation"},{"rate":"5-10","effect":"Wound healing complications"}]},"_chembl":{"chemblId":"CHEMBL1742982","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bevacizumab is a humanized monoclonal antibody that binds and neutralizes VEGF-A, preventing its interaction with VEGF receptors on endothelial cells. Aflibercept is a soluble VEGF receptor fusion protein that acts as a decoy receptor, trapping VEGF ligands. The deferred strategy involves sequential or conditional use of aflibercept after bevacizumab, potentially managing resistance or optimizing anti-angiogenic therapy.","oneSentence":"This combination uses bevacizumab (an anti-VEGF monoclonal antibody) with deferred aflibercept (a VEGF trap) to inhibit vascular endothelial growth factor signaling, reducing abnormal blood vessel formation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:04:04.172Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer (bevacizumab established; aflibercept deferred strategy investigational)"},{"name":"Potentially other solid tumors with VEGF-dependent angiogenesis"}]},"trialDetails":[{"nctId":"NCT03321513","phase":"PHASE3","title":"DRCR.Net Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DME","status":"COMPLETED","sponsor":"Jaeb Center for Health Research","startDate":"2017-12-07","conditions":"Diabetic Macular Edema","enrollment":270}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Avastin"],"phase":"phase_3","status":"active","brandName":"Bevacizumab + Deferred Aflibercept Group","genericName":"Bevacizumab + Deferred Aflibercept Group","companyName":"Jaeb Center for Health Research","companyId":"jaeb-center-for-health-research","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses bevacizumab (an anti-VEGF monoclonal antibody) with deferred aflibercept (a VEGF trap) to inhibit vascular endothelial growth factor signaling, reducing abnormal blood vessel formation. Used for Metastatic colorectal cancer (bevacizumab established; aflibercept deferred strategy investigational), Potentially other solid tumors with VEGF-dependent angiogenesis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}